A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)

Diabetes Therapy - Trang 1-13 - 2024
Yushi Hirota1, Yasumasa Kakei2, Junta Imai3, Hideki Katagiri3, Ken Ebihara4, Jun Wada5, Junichi Suzuki6, Tatsuhiko Urakami6, Takashi Omori7, Wataru Ogawa1
1Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
2Clinical and Translational Research Center, Kobe University Hospital, Kobe, Japan
3Department of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Miyagi, Japan
4Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan
5Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
6Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan
7Division of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Tóm tắt

Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing the efficacy of antidiabetes drugs for these rare conditions have been limited, however. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which lower glycemia independently of insulin action, have shown efficacy for type 2 diabetes with insulin resistance. We here investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin for treatment of insulin resistance syndrome and lipoatrophic diabetes. The trial was conducted at five academic centers in Japan and included seven patients with insulin resistance syndrome and one patient with lipoatrophic diabetes. Participants received 10 mg of empagliflozin daily. If the hemoglobin A1c (HbA1c) level was ≥ 7.0% (52 mmol/mol) after 12 weeks, the dose was adjusted to 25 mg. The study duration was 24 weeks, and the primary outcome was the change in HbA1c level by the end of the treatment period. Safety evaluations were performed for all participants. By the end of the 24-week treatment period, the mean HbA1c level for all eight patients had decreased by 0.99 percentage points (10.8 mmol/mol) (95% confidence interval [CI], 0.59 to 1.38 percentage points, 6.6 to 14.9 mmol/mol) and the mean fasting plasma glucose concentration had declined by 63.9 mg/dL (3.55 mmol/L) (95% CI 25.5 to 102.3 mg/dL, 1.42 to 5.68 mmol/L). Continuous glucose monitoring revealed a reduction in mean glucose levels from 164.3 ± 76.1 to 137.6 ± 46.6 mg/dL (9.13 ± 4.23 to 7.65 ± 2.59 mmol/L) as well as an increase in the time in range (70–180 mg/dL) from 58.9 ± 36.1% to 70.8 ± 18.3%. Seventeen mild adverse events were recorded in five individuals throughout the study period. No severe events were reported. The mean body mass showed a slight decrease and the mean serum ketone body concentration showed a slight increase during treatment. Our results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes. jRCTs2051190029 and NCT04018365.

Tài liệu tham khảo

Semple RK, Savage DB, Cochran EK, Gorden P, O’Rahilly S. Genetic syndromes of severe insulin resistance. Endocr Rev. 2011;32:498–514. Ogawa W, Araki E, Ishigaki Y, et al. New classification and diagnostic criteria for insulin resistance syndrome. Diabetol Int. 2022;13:337–43. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976;294:739–45. Musso C, Cochran E, Moran SA, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004;83:209–22. Takeuchi T, Ishigaki Y, Hirota Y, et al. Clinical characteristics of insulin resistance syndromes: a nationwide survey in Japan. J Diabetes Investig. 2020;11:603–16. Hamaguchi T, Hirota Y, Takeuchi T, et al. Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor. J Diabetes Investig. 2018;9:1224–7. Kushi R, Hirota Y, Ogawa W. Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway. Diabetol Int. 2020;12:62–7. Garg A. Clinical review: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:3313–25. Chiquette E, Oral EA, Garg A, Araújo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;10:375–83. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220–34. Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101:4500–11. Tanaka T, Kusakabe T, Ebihara K, et al. Practice guideline for lipodystrophy syndromes-clinically important diseases of the Japan Endocrine Society (JES). Endocr J. 2021;68:1027–42. Kawana Y, Imai J, Sawada S, Yamada T, Katagiri H. Sodium-glucose cotransporter 2 inhibitor improves complications of lipodystrophy: a case report. Ann Intern Med. 2017;166:450–1. Handelsman Y, Ora EA, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists. The clinical approach to the detection of lipodystrophy—an AACE consensus statement. Endocr Pract. 2013;19:107–16. Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract. 2010;16:310–23. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83–90. The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med. 388:117–27. Anker SD, Butler J, Filippatos G, et al. EMPEROR-preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61. Packer M, Anker SD, Butler J, et al. EMPEROR-reduced trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–24. Nagashima S, Wakabayashi T, Saito N, et al. Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome. J Diabetes Investig. 2020;11:1363–5. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research. JAMA. 2013;310:2191–4. European Medicines Agency, International Conference on Harmonisation. Guideline for good clinical practice E6 (R2)—step 5. 1 December 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf. Accessed 29 May 2019. Zhu X, Lin C, Li L, Hu S, Cai X, Ji L. SGLT2i increased the plasma fasting glucagon level in patients with diabetes: a meta-analysis. Eur J Pharmacol. 2021;903:174145. Roden M, Weng J, Eilbracht J, et al. EMPA-REG MONO Trial Investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised double-blind placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208–19. Ridderstråle M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691–700. Yagi N, Toda A, Mitani K, Kotobuki Y, Ogawa W. A qualitative research study of experiences and perceptions of people living with insulin resistance syndrome or lipoatrophic diabetes in Japan. Diabetes Ther. 2023;14:1345–56. Bonora BM, Avogaro A, Fadini G. Sodium-glucose cotransporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab. 2018;20:25–33. Peters AL, Henry RR, Thakkar P, et al. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care. 2016;39:532–8. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016;7:135–8. Ogawa W, Hirota Y. Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis in patients with type 1 diabetes: metabolic imbalance as an underlying mechanism. J Diabetes Investig. 2019;10:879–82. Kovacs CS, Seshiah V, Swallow R, et al. EMPA-REG PIO™ Trial Investigators. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16:147–58. Mathieu C, Dandona P, Gillard P, et al. DEPICT-2 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial. Diabetes Care. 2018;41:1938–46. Araki E, Watada H, Uchigata Y, et al. Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial. Diabetes Obes Metab. 2020;22:540–8. Kuzuya H, Matsuura N, Sakamoto M, et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes. 1993;42:696–705.
Thông tin
Thông tin xuất bản

Diabetes Therapy

1-13

Thông tin tác giả